Oral delivery of the Sj23LHD-GST antigen by Salmonella typhimurium type III secretion system protects against Schistosoma japonicum infection in mice

PLoS Neglected Tropical Diseases

Volumn 5, Issue 9, 2011, Pages

  Chen, Guo ^a   Dai, Yang ^b   Chen, Jianxiang ^a   Wang, Xiaoting ^b   Tang, Bo ^a   Zhu, Yinchang ^b   Hua, Zichun ^a  

^a NANJING UNIVERSITY   (China)

^b JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HEMOLYSIN; BACTERIAL PROTEIN; CD69 ANTIGEN; EOTAXIN; GAMMA INTERFERON; HERMES ANTIGEN; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; LIVE VACCINE; PROTEIN NIRB; PROTEIN PAGC; RANTES; SALMONELLOSIS VACCINE; SJ23LHD GST ANTIGEN; UNCLASSIFIED DRUG; BACTERIAL VACCINE; HELMINTH ANTIBODY; IMMUNOGLOBULIN G; PARASITE ANTIGEN; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSOL; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMORAL IMMUNITY; IMMUNOBLOTTING; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN SECRETION; SALMONELLA TYPHIMURIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; T LYMPHOCYTE ACTIVATION; TH1 CELL; TYPE III SECRETION SYSTEM; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; FECES; GENE VECTOR; GENETICS; GRANULOMA; IMMUNOLOGY; METHODOLOGY; ORAL DRUG ADMINISTRATION; PARASITE IDENTIFICATION; PARASITOLOGY; PATHOLOGY; SECRETION; VACCINATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FECES; FEMALE; GENETIC VECTORS; GRANULOMA; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-12; MACROPHAGES; MICE; MICE, INBRED BALB C; PARASITE EGG COUNT; SALMONELLA TYPHIMURIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; VACCINATION; VACCINES, SYNTHETIC;

EID: 80053458694     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001313     Document Type: Article

References (42)

1. Ofoezie IE, (1998) Measurement of public health importance of schistosomiasis: problems and prospects. Acta Trop 71: 91-92.
2. Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A, (2010) Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 8: 814-826.
3. McManus DP, Loukas A, (2008) Current status of vaccines for schistosomiasis. Clin Microbiol Rev 21: 225-242.
4. Fenwick A, Webster JP, (2006) Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 19: 577-582.
5. Dai Y, Zhu Y, Harn DA, Wang X, Tang J, et al. (2009) DNA vaccination by electroporation and boosting with recombinant proteins enhances the efficacy of DNA vaccines for Schistosomiasis japonica. Clin Vaccine Immunol 16: 1796-1803.
6. Reynolds SR, Dahl CE, Harn DA, (1994) T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase. J Immunol 152: 193-200.
7. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, et al. (2008) Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis 2: e308.
8. Yang W, Jackson DC, Zeng Q, McManus DP, (2000) Multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice. Vaccine 19: 103-113.
9. Arakawa T, Chong DK, Langridge WH, (1998) Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat Biotechnol 16: 292-297.
10. Huang QS, Greening G, Baker MG, Grimwood K, Hewitt J, et al. (2005) Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet 366: 394-396.
11. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, et al. (2007) Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 45 (Suppl 1): S24-28.
12. Minato S, Iwanaga K, Kakemi M, Yamashita S, Oku N, (2003) Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J Control Release 89: 189-197.
13. Huang JM, Sali M, Leckenby MW, Radford DS, Huynh HA, et al. (2010) Oral delivery of a DNA vaccine against tuberculosis using operator-repressor titration in a Salmonella enterica vector. Vaccine 28: 7523-7528.
14. Cutting SM, Hong HA, Baccigalupi L, Ricca E, (2009) Oral vaccine delivery by recombinant spore probiotics. Int Rev Immunol 28: 487-505.
15. Yeh MK, Liu YT, Chen JL, Chiang CH, (2002) Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. J Control Release 82: 237-247.
16. Ning JF, Zhu W, Xu JP, Zheng CY, Meng XL, (2009) Oral delivery of DNA vaccine encoding VP28 against white spot syndrome virus in crayfish by attenuated Salmonella typhimurium. Vaccine 27: 1127-1135.
17. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, et al. (2006) In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 116: 1946-1954.
18. Panthel K, Meinel KM, Sevil Domenech VE, Trulzsch K, Russmann H, (2008) Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int J Med Microbiol 298: 99-103.
19. Gentschev I, Mollenkopf H, Sokolovic Z, Hess J, Kaufmann SH, et al. (1996) Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. Gene 179: 133-140.
20. Hahn HP, von Specht BU, (2003) Secretory delivery of recombinant proteins in attenuated Salmonella strains: potential and limitations of Type I protein transporters. FEMS Immunol Med Microbiol 37: 87-98.
21. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, et al. (2002) Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20: 142-152.
22. Reynolds SR, Shoemaker CB, Harn DA, (1992) T and B cell epitope mapping of SM23, an integral membrane protein of Schistosoma mansoni. J Immunol 149: 3995-4001.
23. Chen H, Schifferli DM, (2001) Enhanced immune responses to viral epitopes by combining macrophage-inducible expression with multimeric display on a Salmonella vector. Vaccine 19: 3009-3018.
24. Yin W, Cheng W, Shen W, Shu L, Zhao J, et al. (2007) Impairment of Na(+),K(+)-ATPase in CD95(APO-1)-induced human T-cell leukemia cell apoptosis mediated by glutathione depletion and generation of hydrogen peroxide. Leukemia 21: 1669-1678.
25. Sommer F, Huber M, Rollinghoff M, Lohoff M, (1995) CD44 plays a co-stimulatory role in murine T cell activation: ligation of CD44 selectively co-stimulates IL-2 production, but not proliferation in TCR-stimulated murine Th1 cells. Int Immunol 7: 1779-1786.
26. Testi R, Phillips JH, Lanier LL, (1989) T cell activation via Leu-23 (CD69). J Immunol 143: 1123-1128.
27. Lu S, (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21: 346-351.
28. Gryseels B, Polman K, Clerinx J, Kestens L, (2006) Human schistosomiasis. Lancet 368: 1106-1118.
29. Chen G, Wei DP, Jia LJ, Tang B, Shu L, et al. (2009) Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. Cancer Sci 100: 2437-2443.
30. Xu X, Husseiny MI, Goldwich A, Hensel M, (2010) Efficacy of intracellular activated promoters for generation of Salmonella-based vaccines. Infect Immun 78: 4828-4838.
31. Bickle QD, Bogh HO, Johansen MV, Zhang Y, (2001) Comparison of the vaccine efficacy of gamma-irradiated Schistosoma japonicum cercariae with the defined antigen Sj62(IrV-5) in pigs. Vet Parasitol 100: 51-62.
32. Shi YE, Jiang CF, Han JJ, Li YL, Ruppel A, (1990) Schistosoma japonicum: an ultraviolet-attenuated cercarial vaccine applicable in the field for water buffaloes. Exp Parasitol 71: 100-106.
33. Zhang Y, Taylor MG, Bickle QD, Wang H, Ge J, (1999) Vaccination of mice with gamma-irradiated Schistosoma japonicum cercariae. Parasite Immunol 21: 111-117.
34. Zhang MJTF, Gao Y, Ji MJ, Wu GL, (2010) Ultraviolet- attenuated cercariae of Schistosoma japonicum fail to effectively induce a Th1 response in spite of up-egulating expression of cytotoxicity-related genes in C57BL/6 mice. J Biomed Res 24: 277-284.
35. Wynn TA, Hoffmann KF, (2000) Defining a schistosomiasis vaccination strategy- is it really Th1 versus Th2? Parasitol Today 16: 497-501.
36. Garcia TC, Fonseca CT, Pacifico LG, Duraes Fdo V, Marinho FA, et al. (2008) Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice. Acta Trop 106: 162-167.
37. Jankovic D, Aslund L, Oswald IP, Caspar P, Champion C, et al. (1996) Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni. J Immunol 157: 806-814.
38. Zhang R, Yoshida A, Kumagai T, Kawaguchi H, Maruyama H, et al. (2001) Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun 69: 386-391.
39. Miyamasu M, Yamaguchi M, Nakajima T, Misaki Y, Morita Y, et al. (1999) Th1-derived cytokine IFN-gamma is a potent inhibitor of eotaxin synthesis in vitro. Int Immunol 11: 1001-1004.
40. Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, et al. (2011) Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 92: 128-140.
41. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, et al. (2006) Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24: 4554-4561.
42. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, et al. (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 6: 78-83.